Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats

Neurosci Lett. 1998 Apr 3;245(2):61-4. doi: 10.1016/s0304-3940(98)00170-0.

Abstract

In the present study, the in vivo neuroprotective effects of melatonin, as an antioxidant, were assessed in Sprague-Dawley rats with a unilateral lesion of substantia nigra (SN) caused by a stereotaxic injection of neurotoxin, 1-methyl-4-phenylpyridinium (MPP+). When expressed as a percentage ratio of lesioned to intact side, increased lipid peroxidation product (malondialdehyde, MDA, 117% of control) and decreased tyrosine hydroxylase (TH) enzyme activity (60% of control) in SN were observed 4 h after MPP+ lesion. In contrast, however, melatonin treatment prevented MPP+ neurotoxicity by the almost complete recovery of MDA (99% of control) and TH levels (96% of control), indicating the potent antioxidative effects of melatonin. In addition, further reduction of TH enzyme activity (52% of control) was seen 1 week after MPP+ infusion. Continuous (twice a day for 5 days), not acute (4 h) treatment with melatonin produced the partial, but not statistically significant, recovery of TH enzyme activity (71% of control), when sacrificed 1 week after MPP+ lesion. Taken together, the present results support the hypothesis that melatonin may provide the useful therapeutic strategies for the treatment of oxidative stress-induced neurodegenerative disease such as Parkinson's disease (PD).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenylpyridinium / toxicity*
  • Animals
  • Antioxidants / pharmacology
  • Dopamine / physiology*
  • Dopamine Agents / pharmacology*
  • Female
  • Male
  • Melatonin / pharmacology*
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / physiology
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Substantia Nigra / cytology
  • Substantia Nigra / drug effects*

Substances

  • Antioxidants
  • Dopamine Agents
  • Melatonin
  • 1-Methyl-4-phenylpyridinium
  • Dopamine